PRESS RELEASES

March 6, 2018
TCR2 Therapeutics to Present at the Cowen and Company 38th Annual Healthcare Conference and Needham & Company 17th Annual Healthcare Conference

February 5, 2018
TCR2 Therapeutics to Present at the 2018 Keystone Symposia Conference on Emerging Cellular Therapies: T Cells and Beyond

January 3, 2018
TCR2 Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

November 9, 2017
TCR2 Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference

November 2, 2017
TCR2 Therapeutics Appoints Cell Therapy Pioneer Dr. Stephan Grupp to Advisory Board

October 31, 2017
TCR2 Therapeutics to Present New Data from its TRuC TM T Cell Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 11, 2017
TCR2 Therapeutics Appoints Leading Cell Therapy Expert as Chief Medical Officer

September 15, 2017
TCR2 Therapeutics Named One of the 15 Innovative Immuno-Oncology Biotechs to Watch in 2018 by Immuno-Oncology Frontiers

August 29, 2017
TCR2 Therapeutics to Present Solid Tumor Data at CAR-TCR Summit and CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

August 8, 2017
TCR2 Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference

June 13, 2017
TCR2 Therapeutics Presents Positive Solid Tumor Data for its Novel TRuCâ„¢ Engineered T Cell Therapies at the World Preclinical Congress

May 16, 2017
TCR2 Therapeutics to Present at the 2017 UBS Global Healthcare Conference

February 28, 2017
TCR2 Therapeutics to Present at the Cowen and Company 37 th Annual Health Care Conference

December 7, 2016
TCR2 Therapeutics Launches from Stealth Mode to Accelerate Development of Novel Cancer Immunotherapies